Provectus Pharmaceuticals Inc. is a development-stage biopharmaceutical study focused on oncology and dermatology therapies. The company recently announced that the results of its phase II trial showed comparable trends to phase I survival data for 20 subjects with metastatic melanoma.
The one-year overall survival data of its lead oncology agent PV-10 showed longer overall and disease specific survival for subjects that were responsive to the agent, relative to those who did not experience a robust response. In addition, several subjects experienced spontaneous regression of untreated tumors after PV-10 treatment of other tumors.
The company also announced that Professor John F. Thompson, MD, professor of melanoma and surgical oncology at the University of Sydney, director of the Melanoma Institute Australia, and lead investigator of the phase II study of PV-10 for Metastatic Melanoma, recently presented the study results at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany.
“We are very excited by these new results presented by Professor Thompson, especially the first reported objective evidence of potential systemic benefit in visceral organs. We look forward to the possibility of augmenting these results with data from the next 20 subjects, which we expect will be available in the first quarter of 2010. Progress with our expanded access program for PV-10, the means through which certain qualified patients can receive PV-10 on a compassionate use basis, is also heartening as we continue development of the agent toward licensure,” Craig Dees, PhD, CEO of Provectus stated in the press release.